Apellis Pharmaceuticals Stock Price. Everything You Need To Know About The Apellis Pharmaceuticals Stock!
Apellis Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. The company is headquartered in Waltham, Massachusetts and currently employs 767 full-time employees. The company went IPO on 2017-11-09. The firm is focused on the discovery, development and commercialization of therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. Its SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). The Company’s EMPAVELI (pegcetacoplan) is the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) is the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has an approval for the treatment of PNH in Saudi Arabia, Australia, and the United Kingdom. Systemic pegcetacoplan markets under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union and United Kingdom.
Apellis Pharmaceuticals Stock Price. Everything You Need To Know About The Apellis Pharmaceuticals Stock! performance
- Employees 767
- Company HQ Waltham
- Website https://apellis.com/
- APLS Asset Type Common Stock
- APLS Market Capitalization 6B
- Earnings Per Share -4.45
- Dividends Per Share None
- Dividend Date None
- Quarterly Earnings Growth 0
Looking to invest in Apellis Pharmaceuticals from Malaysia, Thailand, Indonesia, or Vietnam? Look no further than Zorion, the leading investment platform offering real US stocks and Pre-IPO companies to retail investors in Southeast Asia. Apellis Pharmaceuticals is a pioneering biopharmaceutical company focused on transforming the lives of patients suffering from serious autoimmune and inflammatory diseases. With Zorion’s investment insights and recommendations, you can make informed decisions about investing in this promising stock. Our platform also provides access to educational materials and resources, empowering you to expand your investment knowledge. Start your journey with Zorion and invest in Apellis Pharmaceuticals today.
